DK1786273T3 - Sekventielle proteinisolerings- og oprensningsplaner med affinitetskromatografi - Google Patents

Sekventielle proteinisolerings- og oprensningsplaner med affinitetskromatografi Download PDF

Info

Publication number
DK1786273T3
DK1786273T3 DK05791084.6T DK05791084T DK1786273T3 DK 1786273 T3 DK1786273 T3 DK 1786273T3 DK 05791084 T DK05791084 T DK 05791084T DK 1786273 T3 DK1786273 T3 DK 1786273T3
Authority
DK
Denmark
Prior art keywords
plasma
ligand
ligands
protein
column
Prior art date
Application number
DK05791084.6T
Other languages
English (en)
Inventor
Steven James Burton
Baldev Baines
John Curling
Dwun-Hou Chen
Christopher Bryant
David John Hammond
Timothy Keith Hayes
Original Assignee
Prometic Biosciences Ltd
The American Nat Red Cross
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Ltd, The American Nat Red Cross filed Critical Prometic Biosciences Ltd
Application granted granted Critical
Publication of DK1786273T3 publication Critical patent/DK1786273T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (14)

1. Fremgangsmåde til sekventiel proteinisolering og oprensning omfattende (i) tilvejebringelse af en plasmaprøve, (ii) tilvejebringelse af ligander, som hver især binder specifikt til et målprotein i den biologiske prøve, hvori hver af liganderne valgfrit knyttes til et underlag for at danne ligand-underlagskomplekser, (iii) at liganderne eller ligandunderlagskomplekserne sekventielt og i en forudbestemt rækkefølge bringes i kontakt med plasmaprøven for at gøre det muligt for hver enkelt ligand eller ligandunderlagskompleks sekventielt at binde målproteinet fra plasmaprøven, hvori den forudbestemte rækkefølge, i hvilken liganderne eller ligand-underlagskomplekserne bringes i kontakt med plasmaprøven, resulterer i binding af plasminogen før IgG og IgG før albumin, og hvori den biologiske prøve ikke behandles ved hjælp af et forbehandlingstrin valgt fra gruppen bestående af alkoholudfældning, cryoudfældning, fjernelse af lipider og/eller lipidproteiner, euglobulinudfældning eller en kombination deraf, forud for kontakten, (iv) eluering af målproteinet bundet til hver af liganderne eller ligand-underlagskomplekserne og (v) sekventiel isolering af målproteinet fra den biologiske prøve.
2. Fremgangsmåde ifølge krav 1, hvori målproteinerne omfatter fibrinogen, alpha-1 proteinaseinhibitor, apolipoprotein A1, immunglobuliner, paraoxonase, koagulationsfaktorer, vWF/FVIll, albumin, plasminogen eller en kombination deraf.
3. Fremgangsmåde ifølge krav 2, hvori fibrinogen isoleres fra plasma før IgG.
4. Fremgangsmåde ifølge krav 2, hvori aktiviteten af paraoxonase bibeholdes i den biologiske prøve under proteinisoleringen.
5. Fremgangsmåde ifølge krav 2, hvori vWF/FVIll isoleres fra plasma forud for plasminogen.
6. Fremgangsmåde ifølge krav 2, hvori apolipoprotein A1 isoleres fra plasma før IgG.
7. Fremgangsmåde ifølge krav 2, hvori alpha-1 proteinaseinhibitor isoleres fra plasma efter albumin.
8. Fremgangsmåde ifølge krav 2, hvori plasminogen isoleres fra plasma forud for fibrinogen.
9. Fremgangsmåde ifølge krav 1, hvori liganden omfatter et peptid, polypeptid, peptidefterlignende stof, lille molekyle, farvestof, en triazinholdig forbindelse, et antistofeller antigenbindende fragment, nukleinsyre-baseret molekyle, non-polypeptid- eller nukleotid-baseret molekyle, kulhydrat, kulhydratefterlignende stoffer, lipider, uorganisk materiale, inhibitor, substrat eller enhver kombination deraf.
10. Fremgangsmåde ifølge krav 9, hvori liganderne omfatter peptider bestående af 3 til 5, 8, 10 eller 15 aminosyrer.
11. Fremgangsmåde ifølge krav 1, hvori underlaget omfatter et syntetisk materiale, et naturligt materiale eller begge.
12. Fremgangsmåde ifølge krav 1, hvori underlaget omfatter agarose, polyacrylamid, dextran, cellulose, polysaccharid, nitrocellulose, silica, alumina, aluminumoxid, titania, titaniumoxid, zirconia, styren, polyvinyldifluorid nylon, copolymer af styren og divinylbenzen, polymethacrylatester, derivatiseret azlactonpolymer eller -copolymer, glass, cellulose, agarose, derivater af enhver af de foregående og kombinationer af enhver af de foregående.
13. Fremgangsmåde ifølge krav 1, hvori underlaget er en harpiksperle.
14. Fremgangsmåde ifølge krav 1, hvori plasmaprøven behandles med et buffermiddel forud for kontakttrinnet med henblik på yderligere at konservere koncentrationen og aktiviteten af et eller flere målmidler i plasmaprøven.
DK05791084.6T 2004-08-20 2005-08-19 Sekventielle proteinisolerings- og oprensningsplaner med affinitetskromatografi DK1786273T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60286804P 2004-08-20 2004-08-20
PCT/US2005/029739 WO2006023831A2 (en) 2004-08-20 2005-08-19 Sequential protein isolation and purification schemes by affinity chromatography

Publications (1)

Publication Number Publication Date
DK1786273T3 true DK1786273T3 (da) 2019-02-18

Family

ID=35968252

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05791084.6T DK1786273T3 (da) 2004-08-20 2005-08-19 Sekventielle proteinisolerings- og oprensningsplaner med affinitetskromatografi

Country Status (15)

Country Link
US (1) US8198407B1 (da)
EP (1) EP1786273B1 (da)
JP (1) JP4970260B2 (da)
CN (1) CN101035439B (da)
AU (1) AU2005277190B2 (da)
BR (1) BRPI0514435B8 (da)
CA (1) CA2576963C (da)
DK (1) DK1786273T3 (da)
ES (1) ES2710025T3 (da)
MX (1) MX2007002085A (da)
MY (1) MY147996A (da)
PL (1) PL1786273T3 (da)
PT (1) PT1786273T (da)
TW (1) TWI392685B (da)
WO (1) WO2006023831A2 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555543B2 (en) 2000-08-04 2003-04-29 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
KR20150080004A (ko) 2003-05-15 2015-07-08 앰피오 파마슈티컬스 인코퍼레이티드 Ｔ-세포 매개성 질환의 치료 방법
WO2009025754A2 (en) * 2007-08-17 2009-02-26 Csl Behring Gmbh Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
AU2011250839B2 (en) * 2007-08-17 2012-07-12 Csl Behring Gmbh Methods for purification of alpha-1-antitrypsin and apolipoprotein A-1
CN101396650B (zh) * 2007-09-26 2010-12-22 中国科学院大连化学物理研究所 一种固定钛离子亲和色谱材料及其制备和应用
WO2009131526A1 (en) * 2008-04-22 2009-10-29 Ge Healthcare Bio-Sciences Ab Chromatography medium
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
FR2942233B1 (fr) * 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
JP5458183B2 (ja) * 2009-10-01 2014-04-02 エフ．ホフマン−ラ ロシュ アーゲー 多段階最終濾過方法
JP2012050386A (ja) * 2010-09-01 2012-03-15 Kaneka Corp ２種類以上の多孔質充填剤を充填するカラム
JP5836577B2 (ja) * 2010-09-14 2015-12-24 株式会社カネカ クリングル配列を有する蛋白質またはペプチドを精製または除去するアフィニティ担体の製造方法、その精製方法、除去方法
JPWO2012036140A1 (ja) * 2010-09-14 2014-02-03 株式会社カネカ クリングル配列を有する蛋白質またはペプチドを精製または除去するアフィニティ担体、及びそれを用いた精製方法、除去方法
AU2011343813B2 (en) 2010-12-15 2015-05-21 Takeda Pharmaceutical Company Limited Eluate collection using conductivity gradient
MY172699A (en) 2011-10-10 2019-12-10 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
WO2013055734A1 (en) 2011-10-10 2013-04-18 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
MX355446B (es) 2011-10-28 2018-04-18 Ampio Pharmaceuticals Inc Tratamiento de rinitis.
PL2871968T3 (pl) * 2012-07-11 2016-11-30 Izolaty białek ziemniaczanych
CN103351431A (zh) * 2012-11-13 2013-10-16 蔡胜和 一种凝血八因子及其变异体纯化方法
BR112015017958A2 (pt) * 2013-02-01 2017-07-11 Ampio Pharmaceuticals Inc métodos para produzir dicetopiperazinas e composições contendo dicetopiperazinas
EP2968315B1 (en) 2013-03-15 2020-06-03 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
WO2014186874A1 (en) 2013-05-23 2014-11-27 Yyz Pharmatech, Inc. Methods and compositions for enzyme linked immuno and hybridization mass spectrometric assay
US9663553B2 (en) 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma
JP2017512131A (ja) * 2014-02-04 2017-05-18 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 特異的アントラキノン染料リガンド構造の使用による抗体、抗体断片又はそれらの操作された変異体の精製方法
FR3018450B1 (fr) 2014-03-11 2016-04-15 Lab Francais Du Fractionnement Procede de preparation de proteines plasmatiques humaines
WO2016028790A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
CN108779166A (zh) * 2015-10-21 2018-11-09 科博锐恩生物制品有限责任公司 从血浆纯化蛋白质的方法
CN105504131B (zh) * 2016-01-26 2018-07-17 重庆希尔康血液净化器材研发有限公司 用于血液净化清除β2-微球蛋白的树脂的制备方法
EP3205665A1 (en) * 2016-02-11 2017-08-16 Octapharma AG Method of separating factor viii from blood products
CA3104041A1 (en) * 2018-06-22 2019-12-26 Somalogic, Inc. Improved proteomic multiplex assays
US11991994B2 (en) 2019-10-30 2024-05-28 Future Fields Cellular Agriculture and Research LTD. Method for producing recombinant proteins in insects

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE392038B (sv) 1971-09-08 1977-03-14 Kabi Ab Forfarande for isolering av antitrombin ur blod eller blodprodukter
US4137307A (en) 1973-11-15 1979-01-30 The Green Cross Corporation Process for preparing haptoglobin aqueous solution using strong anion exchanger
US4061735A (en) 1973-11-15 1977-12-06 The Green Cross Corporation Haptoglobin in aqueous solution and process for preparing the same
US4011067A (en) 1974-01-30 1977-03-08 Minnesota Mining And Manufacturing Company Filter medium layered between supporting layers
US3943245A (en) * 1974-02-14 1976-03-09 Armour Pharmaceutical Company Purification of plasminogen
CA1064396A (en) 1975-02-18 1979-10-16 Myer L. Coval Fractional precipitation of gamma globulin with polyethylene glycol
JPS52125609A (en) 1976-04-09 1977-10-21 Green Cross Corp:The Purification of agglutination factor viii
JPS56106594A (en) 1980-01-25 1981-08-24 Green Cross Corp:The Stabilizing method of plasminogen
JPS5716824A (en) 1980-07-03 1982-01-28 Green Cross Corp:The Plasminogen pharmaceutical and stabilizing method thereof
US4371520A (en) 1981-10-28 1983-02-01 The Green Cross Corporation Process for preparing immunoglobulin suitable for intravenous injection
JPS5967228A (ja) 1982-10-07 1984-04-16 Green Cross Corp:The 寒冷不溶性グロブリンの凍結乾燥方法
JPS63108000A (ja) 1986-05-15 1988-05-12 Green Cross Corp:The 第８因子の精製方法
US5187155A (en) 1989-06-23 1993-02-16 Board Of Regents, The University Of Texas System Anticoagulant peptides
US5138034A (en) 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
US5576220A (en) 1993-02-19 1996-11-19 Arris Pharmaceutical Corporation Thin film HPMP matrix systems and methods for constructing and displaying ligands
JP3128398B2 (ja) 1993-10-13 2001-01-29 三洋電機株式会社 部品装着装置における部品認識用照明装置
US6117996A (en) 1995-09-20 2000-09-12 Novo Nordisk A/S Triazine based ligands and use thereof
DE59509979D1 (de) 1995-09-22 2002-02-07 Zlb Bioplasma Ag Bern Verfahren zur Gewinnung von Immunglobulinen aus Fraktionen, die bei der Fraktionierung von menschlichem Blutplasma entstehen
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
US6037457A (en) * 1997-01-31 2000-03-14 The University Of North Carolina At Chapel Hill Method for recombinant fibrinogen production
US5985836A (en) 1998-07-31 1999-11-16 Bayer Corporation Alpha-1 proteinase inhibitor binding peptides
US6214221B1 (en) 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
NZ513242A (en) * 1999-02-22 2003-10-31 Henry B Kopf Purification of biological substances

Also Published As

Publication number Publication date
CA2576963C (en) 2015-02-17
TWI392685B (zh) 2013-04-11
JP2008510724A (ja) 2008-04-10
EP1786273B1 (en) 2018-11-14
TW200621798A (en) 2006-07-01
BRPI0514435B8 (pt) 2021-05-25
EP1786273A2 (en) 2007-05-23
BRPI0514435B1 (pt) 2019-08-13
ES2710025T3 (es) 2019-04-22
CN101035439A (zh) 2007-09-12
WO2006023831A3 (en) 2006-06-08
AU2005277190A1 (en) 2006-03-02
BRPI0514435A (pt) 2008-06-10
US8198407B1 (en) 2012-06-12
PL1786273T3 (pl) 2019-05-31
WO2006023831A2 (en) 2006-03-02
JP4970260B2 (ja) 2012-07-04
MX2007002085A (es) 2007-07-19
EP1786273A4 (en) 2010-05-26
AU2005277190B2 (en) 2011-03-03
CN101035439B (zh) 2013-02-06
PT1786273T (pt) 2019-02-19
MY147996A (en) 2013-02-28
CA2576963A1 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
DK1786273T3 (da) Sekventielle proteinisolerings- og oprensningsplaner med affinitetskromatografi
US7396468B2 (en) Methods and system for protein separation
KR101293504B1 (ko) 혼합형 또는 다중형 수지를 사용하는 인자 ｖⅰⅰⅰ의 정제
KR101883610B1 (ko) 재조합 adamts13 및 기타 단백질을 정제하는 방법, 그리고 이들의 조성물
US10266566B2 (en) Protease-resistant peptide ligands
JP4250769B2 (ja) 高度に精製されたｖＷＦまたは因子ＶＩＩＩ／ｖＷＦ複合体を得る方法
Winge et al. Development, upscaling and validation of the purification process for human-cl rhFVIII (Nuwiq®), a new generation recombinant factor VIII produced in a human cell-line
Kovács et al. Medicinal chemistry meets proteomics: fractionation of the human plasma proteome
JP4841618B2 (ja) タンパク質を精製するための方法
EP2102335A1 (en) Purification of factor xi
Bachi et al. Performance of combinatorial peptide libraries in capturing the low-abundance proteome of red blood cells. 2. Behavior of resins containing individual amino acids
FI119377B (fi) Menetelmä tekijän IX valmistamiseksi biologisista lähteistä
CA2569821A1 (en) Process for protein isolation
Bastek et al. Discovery of Alpha-1-proteinase inhibitor binding peptides from the screening of a solid phase combinatorial peptide library
Clifton et al. Use of proteomics for validation of the isolation process of clotting factor IX from human plasma
CN108699133B (zh) 从血液产品分离因子viii的方法
Garg Purification and Production of Therapeutic Grade Proteins Vipin K. Garg,* Maureen AC Costello, and Barbara A. Czuba* Bio-Response, Inc. Hayward, California
JP6024101B2 (ja) 血液凝固因子又は細胞接着因子に対する吸着剤及び精製方法
US11919924B1 (en) Methods of purifying and producing an adalimumab antibody
Isu et al. Process-and Product-Related Foulants in Virus Filtration. Bioengineering 2022, 9, 155
WO2007149281A2 (en) Combinatorial library for proteomic investigations